CEA (Original year of values) | Treatment vs. Comparator | ICER summary/estimate [2013 US$] | Unit of effectiveness | Incremental cost [2013 US$] | Incremental effectiveness |
---|---|---|---|---|---|
Abidia 2003 (2000) [48] | HBOT vs. control | Dominant | Additional wound healed | −7,596 | 0.625 |
Apelqvist 1996 (1993) [49] | Cadexomer iodine ointment vs. standard treatment | Dominanta | Additional wound healed | −119 | 0.183 |
Edmonds 1999 (1996) [50] | Filgrastim vs. placebo | Dominanta,b | Hospital-free day gained | −7,738 | 7.5 |
Guo 2003 (2001) [51] | HBOT + SC vs. SC alone | 3508a | QALY gained | 2,137 | 0.609 |
Habacher 2007 (2001) [52] | Intensified treatment vs. SC | Dominanta | Patient-year gained | −7,625 | 2.97 |
Horswell 2003 (1999) [53] | Staged management diabetes foot program vs. SC | Dominanta | Foot-related hospitalization avoided | −7,848 | 0.41 |
Jansen 2009 (2006) [54] | Ertapenem vs. Piperacillin/Tazobactam | Dominanta | Lifetime QALY gained | −822 | 0.12 |
Jeffcoate 2009c (2007) [55] | Hydrocolloid (Aquacel) vs. antiseptic (Inadine) | 1449a | Additional wound healed | 14 | 0.01 |
Jeffcoate 2009c (2007) [55] | Antiseptic (Inadine) vs. non-adherent dressing | 1590a | Additional wound healed | 80 | 0.05 |
McKinnon 1997 (1994) [56] | Ampicillin/sulbactam vs. imipenem/cilastatin | Dominanta | Hospitalization day avoided | −5,891 | 3.5 |
Persson 2000 (1999) [57] | Becaplermin plus GWC (unspecified) vs. GWC alone | Dominanta | Ulcer-free month gained | −628 | 0.81 |
Piaggesi 2007 (2006) [58] | Total contact casting vs. Optima Diab device | 8,578 | Additional wound healed | 858 | 0.1 |
Redekop 2003 (1999) [59] | Apligraf (skin substitute) + GWCd vs. GWC alone | Dominanta | Ulcer-free month gained | −1,223 | 1.53 |
Allenet 2000 (1998) [60] | Dermagraft (human dermal replacement) vs. SC | 70,961a | Additional wound healed | 12,652 | 0.178 |
Ghatnekar 2002 (2000) [61] | Promogran dressing plus GWCe vs. GWC alone | Dominanta | Additional wound healed | −294 | 0.042 |
Ghatnekar 2001 (1999) [62] | Becaplermin gel (containing recombinant human platelet-derived growth factor) plus GWCf vs. GWC alone | Dominanta | Ulcer-free month gained | −794 | 0.81 |
Hailey 2007 (2004) [63] | HBOT + SC vs. SC alone | Dominant | QALY gained | −9,337 | 0.63 |